At the recent American Academy of Dermatology (AAD) Annual Meeting, Robert Bissonnette, MD, presented late-breaking data from the ICONIC-LEAD (NCT06095115) study evaluating icotrokinra, an oral IL-23 receptor antagonist, for patients with moderate-to-severe plaque psoriasis. The phase 3 study demonstrated significant efficacy at week 16, with further improvements observed through week 24. In an interview with Dermatology Times, Dr. Bissonnette, lead investigator and chairman at Indero, shared his insights on the data and what the results might mean for clinicians and patients down the road.
